Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

THINPAD

Financiado

Cerrado

Targeting the HIV 1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance

AIDS is one of the most serious pandemic diseases of the modern era. Although current therapies based on targeting key processes of the HIV replication cycle are potent and selective, several clinical failures are recorded due to... ver más

31/08/2016

UNISI

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI SIENA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-08-31 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UNISI

0.00€ | Lider

CONSORCI INSTITUT D INVESTIG...

N.D. | Participante

UNISTRA

N.D. | Participante

IRBM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2011-24671 HDAC6 COMO NUEVO FACTOR DE RESTRICCION CON ACTIVIDAD ANTIRRE... 121K€ Cerrado

PID2020-117646RB-I00 EXPLORANDO NUEVAS ESTRATEGIAS EN ENFERMEDADES VIRICAS Y TUBE... 171K€ Cerrado

DESARROLLO CLÍNICO INMUNÓGENO HTI DESARROLLO CLÍNICO INMUNÓGENO HTI 848K€ Cerrado

BIO2013-48788-C2-1-R FIDELIDAD DE POLIMERASAS VIRALES QUE COPIAN MOLDES ARN Y SU... 133K€ Cerrado

BIO2016-76640-R DISEÑO Y DESARROLLO DE NUEVOS INHIBIDORES DEL VIH BASADOS EN... 182K€ Cerrado

SAF2010-21617-C02-01 PROGRAMA DE INVESTIGACION ANTIVIRAL VIH-VHC 121K€ Cerrado

Líder del proyecto

UNIVERSITA DEGLI STUDI DI SIENA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto AIDS is one of the most serious pandemic diseases of the modern era. Although current therapies based on targeting key processes of the HIV replication cycle are potent and selective, several clinical failures are recorded due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies. The objective of the THINPAD proposal is to discover and develop novel anti-HIV agents targeting the HIV nucleocapsid protein(NC), which is one of the most conserved sequence within HIV strains and is highly required for HIV replication, being therefore a primary target to overcome antiretroviral drug-resistance. The proposal originates from the successful FP6 TRIoH project and presents a multidisciplinary approach to develop anti-HIV drugs, ready for early clinical trials, that could be resistant to viral mutation since targeting a highly conserved sequence. The consortium consists of experts in the anti-HIV field which have an extensive expertise in targeting NC. Partner 1 has studied the NC dynamics and discovered small molecule NC modulators by in silico approaches. Partner 2 has developed biophysical methods to monitor the NC functions and the interaction with small molecules. Partner 3 developed a complete approach of biochemistry-, retrovirology- and microscopy-based techniques to monitor NC during HIV assembly, maturation and reverse transcription. Partner 4 is a SME founded by scientists who participated in the development of Raltegravir, which will have a leading role in the project together with Partner 5 (SME) by driving the discovery phase and pre-clinical investigation, favouring the translation of results into innovative applications for health. It is worth noting that the consortium already possesses small molecules endowed with low-micromolar inhibitory activity in cell against HIV and active against resistant strains. Notably, these molecules interact with the NC but not with the usual anti-HIV targets

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores